Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies

Current Topics in Medicinal Chemistry

Volumn 11, Issue 22, 2011, Pages 2788-2796

  Binda, Claudia ^a   Milczek, Erika M ^b   Bonivento, Daniele ^a   Wang, Jin ^b   Mattevi, Andrea ^a   Edmondson, Dale E ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b EMORY UNIVERSITY   (United States)

Author keywords

Depression; Flavin; Monoamine oxidase; Neuroprotection; Parkinson's disease

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CALCIUM CHANNEL; CLORGYLINE; CYCLOPROPYLAMINE DERIVATIVE; CYTOCHROME P450; GLUTAMIC ACID; HYDRAZINE DERIVATIVE; IDAZOXAN; IMIDAZOLINE; ISOCARBOXAZID; LAZABEMIDE; LEVODOPA; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; OCTAMOXIN; PHENELZINE; PROPARGYLAMINE DERIVATIVE; RASAGILINE; SAFINAMIDE; SELEGILINE; SODIUM CHANNEL; TRANYLCYPROMINE; UNCLASSIFIED DRUG; ZONISAMIDE;

ARTICLE; DEPRESSION; DRUG MECHANISM; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE;

ANIMALS; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NERVOUS SYSTEM DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 82055192229     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611798184355     Document Type: Article

References (69)

1. Shih, J.C.; Chen, K.; Ridd, M.J. Monoamine oxidases: from genes to behavior. Annu. Rev. Neurosci., 1999, 22,197-217.
2. Edmondson, D.E.; Binda, C.; Wang, J.; Upadhyay, A.K.; Mattevi, A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry, 2009, 48, 4220-4230.
3. Brunner, H.G.; Nelen, M.R.; Vanzandvoort, P.; Abeling, N.G.; van Gennip, A.H., Wolters, E.C.; Kuiper, M.A.; Ropers, H.H.; Vanoost, B.A. X-linked borderline mental retardation with prominent behavioral disturbance: phenotype, genetic localization, and evidence for disturbed monoamine metabolism. Am. J. Human Genet., 1993, 52, 1032-1039.
4. Alia-Klein, N.; Goldstein, R.Z.; Kriplani, A.; Logan, J.; Tomasi, D.; Williams, B.; Telang, F.; Shumay, E.; Biegon, A.; Craig, I.W.; Henn, F.; Wang, G.J.; Volkow, N.D.; Fowler, J.S. Brain monoamine oxidase A activity predicts trait aggression. J. Neurosci., 2008, 28, 5099-5104.
5. Beaver, K.M.; DeLisi, M.; Vaughn, M.G.; Barnes, J.C. Monoamine oxidase A genotype is associated with gang membership and weapon use. Compr. Psychiatr., 2010, 51, 130-134.
6. Shih, J.C. Monoamine oxidases: from tissue homogenates to transgenic mice. Neurochem. Res., 2007, 32, 1757-1761.
7. Whibley, A.; Urquhart, J.; Dore, J.; Willatt, L.; Parkin, G.; Gaunt, L.; Black, G.; Donnai, D.; Raymond, F.L. Deletion of MAOA and MAOB in a male patient causes severe developmental delay, intermittent hypotonia and stereotypical hand movements. Eur. J. Hum. Genet., 2010, 18(10),1095-1099.
8. Nicotra, A.; Pierucci, F.; Parvez, H.; Senatori, O. Monoamine oxidase expression during development and aging. Neurotoxicology, 2004, 25, 155-165.
9. Cesura, A.M.; Pletscher, A. The new generation of monoamine oxidase inhibitors. Prog. Drug Res., 1992, 38, 171-297.
10. Bosworth, D.M.; Fielding, J.W.; Acosta, M.G.; Demarest, L.M. Use of iproniazid in nontuberculous bone and joint infections. J. Am. Med. Assoc., 1955, 157, 132-136.
11. López-Muñoz, F.; Alamo, C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr. Pharm. Des., 2009, 15, 1563-1586.
12. Callingham, B.A. Drug interactions with reversible monoamine oxidase-A inhibitors. Clin. Neuropharmacol., 1993, 16 (Suppl 2), S42-50.
13. Tobe, E.H. Transdermal selegiline: new opportunity for managing depression. J. Am. Osteopath. Assoc., 2008, 108, 85-86.
14. Rabey, J.M.; Sagi, I.; Huberman, M.; Melamed, E.; Korczyn, A.; Giladi, N.; Inzelberg, R.; Djaldetti, R.; Klein, C.; Berecz, G. Rasagiline Study Group. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin. Neuropharmacol., 2000, 23, 324-330.
15. Binda, C.; Newton-Vinson, P.; Hubalek, F.; Edmondson, D.E.; Mattevi, A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol., 2002, 9, 22-26.
16. Binda, C.; Hubalek, F.; Li, M.; Herzig, Y.; Sterling, J.; Edmondson, D.E.; Mattevi, A. Crystal structures of MAO B in complex with four inhibitors of the N- propargylaminoindan class. J. Med. Chem., 2004, 47, 1767-74.
17. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, D.E.; Mattevi, A. Three- dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. USA, 2005, 102, 12684-12689.
18. Son S.Y.; Ma, J.; Kondou, Y.; Yoshimura, M.; Yamashita, E.; Tsukihara, T. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc. Natl. Acad. Sci. USA, 2008, 105, 5739-5744.
19. Fitzgerald, J.C.; Ufer, C.; De Girolamo, L.A.; Kuhn, H.; Billett, E.E. Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells. J. Neurochem., 2007, 103, 2189-2199.
20. Kaludercic, N.; Takimoto, E.; Nagayama, T.; Feng, N.; Lai, E.W.; Bedja, D.; Chen, K.; Gabrielson, K.L.; Blakely, R.D.; Shih, J.C.; Pacak, K.; Kass, D.A.; Di Lisa, F.; Paolocci, N. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ. Res., 2010, 106, 193-202.
21. Bianchi, P.; Kunduzova, O.; Masini, E.; Cambon, C.; Bani, D.; Raimondi, L.; Seguelas, M.H.; Nistri, S.; Colucci, W.; Leducq, N.; Parini, A. Oxidative stress by monoamine oxidase mediates receptor- independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation, 2005, 112, 3297-3305.
22. Keiser, M.J.; Setola, V.; Irwin, J.J.; Laggner, C.; Abbas, A.I.; Hufeisen, S.J.; Jensen, N.H.; Kuijer, M.B.; Matos, R.C.; Tran, T.B.; Whaley, R.; Glennon, R.A.; Hert, J.; Thomas, K.L.; Edwards, D.D.; Shoichet, B.K.; Roth, B.L. Predicting new molecular targets for known drugs. Nature, 2009, 462, 175-181.
23. Herraiz, T.; Chaparro, C. Human monoamine oxidase enzyme inhibition by coffee and beta- carbolines norharman and harman isolated from coffee. Life Sci., 2006, 78, 795-802.
24. van den Berg, D.; Zoellner, K.R.; Ogunrombi, M.O.; Malan, S.F.; Terre'Blanche, G.; Castagnoli, N. Jr.; Bergh, J.J.; Petzer, J.P. Inhi bition of monoamine oxidase B by selected benzimidazole and caffeine analogues. Bioorg. Med. Chem., 2007, 15, 3692-3702.
25. Binda, C.; Li, M.; Hubalek, F.; Restelli, N.; Edmondson, D.E.; Mattevi, A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci USA, 2003, 100, 9750-9755.
26. Ueda, R.; Suzuki, T.; Mino, K.; Tsumoto, H.; Nakagawa, H.; Hasegawa, M.; Sasaki, R.; Mizukami, T.; Miyata, N. Identification of cell-active lysine specific demethylase 1- selective inhibitors. J. Am. Chem. Soc., 2009, 131, 17536-17537.
27. Binda, C.; Valente, S.; Romanenghi, M.; Pilotto, S.; Cirilli, R.; Karytinos, A.; Ciossani, G.; Botrugno, O.A.; Forneris, F.; Tardugno, M.; Edmondson, D.E.; Minucci, S.; Mattevi, A.; Mai, A. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J. Am. Chem. Soc., 2010, 132, 6827-6833.
28. Upadhyay, A.K.; Borbat, P.P.; Wang, J.; Freed, J.H.; Edmondson, D.E. Determination of the oligomeric states of human and rat monoamine oxidases in the outer mitochondrial membrane and octyl beta-D-glucopyranoside micelles using pulsed dipolar electron spin resonance spectroscopy, Biochemistry, 2008, 47, 1554-1566.
29. Binda, C.; Wang, J.; Li, M.; Hubalek, F.; Mattevi, A.; Edmondson, D.E. Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B. Biochemistry, 2008, 47, 5616-5625.
30. Holt, A.; Berry, M.D.; Boulton, A.A. On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neurotoxicology, 2004, 25, 251-266.
31. Polasek, T.M.; Elliot, D.J.; Somogyi, A.A.; Gillam, E.M.; Lewis, B.C.; Miners, J.O. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br. J. Clin. Pharmacol., 2006, 61, 570-584.
32. Heydendael, W.; Jacobson, L. Differential effects of imipramine and phenelzine on corticosteroid receptor gene expression in mouse brain: potential relevance to antidepressant response. Brain Res., 2008, 1238, 93-107.
33. Chiche, F.; Le Guillou, M.; Chétrite, G.; Lasnier, F.; Dugail, I.; Carpéné C.; Moldes, M.; Fève, B. Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol. Pharmacol., 2009, 75, 1052-1061.
34. Frieling, H.; Bleich, S. Tranylcypromine: new perspectives on an old drug. Eur. Arch. Psychiatry Clin. Neurosci., 2006, 256, 268-273.
35. Salsali, M.; Holt, A.; Baker, G.B. Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol. Neurobiol., 2004, 24, 63-76.
36. Shepard, E.M.; Heggem, H.; Juda, G.A.; Dooley, D.M. Inhibition of six copper- containing amine oxidases by the antidepressant drug tranylcypromine. Biochim. Biophys. Acta., 2003, 1647, 252-259.
37. Forneris, F.; Binda, C.; Battaglioli, E.; Mattevi, A. LSD1: oxidative chemistry for multifaceted functions in chromatin regulation. Trends Biochem. Sci., 2008, 33, 181-189.
38. Karytinos, A.; Forneris, F.; Profumo, A.; Ciossani, G.; Battaglioli, E.; Binda, C.; Mattevi, A. A novel mammalian flavin-dependent histone demethylase. J. Biol. Chem., 2009, 284, 17775-17782.
39. Forneris, F.; Battaglioli, E.; Mattevi, A.; Binda C. New roles of flavoproteins in molecular cell biology: histone demethylase LSD1 and chromatin. FEBS J., 2009, 276, 4304-4312.
40. Mimasu, S.; Sengoku, T.; Fukuzawa, S.; Umehara, T.; Yokoyama, S. Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A. Biochem. Biophys. Res. Commun., 2008, 366, 15-22.
41. Culhane, J.C.; Wang, D.; Yen, P.M.; Cole, P.A. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. J. Am. Chem. Soc., 2010, 132, 3164-3176.
42. Rittenbach, K.A.; Baker, G.B. Involvement of cytochromes P450 2D6, 2B6 and 2C19 in the metabolism of (-)-deprenyl and Nmethyl, N-propargylphenylethylamine. Drug Metab. Lett., 2007, 1, 97-100.
43. Medvedev, A.; Buneeva, O.; Gnedenko, O.; Fedchenko, V.; Medvedeva, M.; Ivanov, Y.; Glover, V.; Sandler, M. Isatin interaction with glyceraldehyde-3-phosphate dehydrogenase, a putative target of neuroprotective drugs: partial agonism with deprenyl. J. Neural. Transm. Suppl., 2006, 71, 97-103.
44. Takahata, K.; Shimazu, S.; Katsuki, H.; Yoneda, F.; Akaike, A. Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J. Neural. Transm., 2006, 113, 151-158.
45. Rascol, O.; Brooks, D.J.; Melamed, E.; Oertel, W.; Poewe, W.; Stocchi, F.; Tolosa, E; LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet, 2005, 365, 947-954.
46. Weinreb, O.; Amit, T.; Sagi, Y.; Drigues, N.; Youdim, M.B. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain. J. Neural. Transm., 2009, 116, 1457-1472.
47. Youdim, M.B.; Weinstock, M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(Npropargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell Mol. Neurobiol., 2001, 21, 555-573.
48. Weinstock, M.; Luques, L.; Poltyrev, T.; Bejar, C.; Shoham, S. Ladostigil prevents age- related glial activation and spatial memory deficits in rats. Neurobiol. Aging, 2009, 32(6),1069-1078
49. Mason, R.P.; Olmstead, E.G.; Jacob, R.F. Antioxidant activity of the monoamine oxidase B inhibitor lazabemide. Biochem. Pharmacol., 2000, 60, 709-716.
50. LeWitt, P.A.; Taylor, D.C. Protection against Parkinson's disease progression: clinical experience. Neurotherapeutics, 2008, 5, 210-225.
51. Wu, M.L.; Deng, J.F. Serotonin toxicity caused by moclobemide too soon after paroxetine- selegiline. J. Chin. Med. Assoc., 2009, 72, 446-449.
52. Bonnet, U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev., 2003, 9, 97-140.
53. Fariello, R.G. Safinamide. Neurotherapeutics, 2007, 4, 110-116.
54. Caccia, C.; Maj, R.; Calabresi, M.; Maestroni, S.; Faravelli, L.; Curatolo, L.; Salvati, P.; Fariello, R.G. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology, 2006, 67, S18-S23.
55. Murata, M. Zonisamide: a new drug for Parkinson's disease. Drugs Today, 2010, 46, 251-258.
56. Raddatz, R.; Savic, S.L.; Bakthavachalam, V.; Lesnick, J.; Jasper, J.R.; McGrath, C.R.; Parini, A.; Lanier, S.M. Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme. J. Pharmacol. Exp. Ther., 2000, 292, 1135-1145.
57. Bonivento, D.; Milczek, E.M.; McDonald, G.R.; Binda, C.; Holt, A.; Edmondson, D.E.; Mattevi, A. Potentiation of Ligand Binding through Cooperative Effects in Monoamine Oxidase B. J. Biol. Chem., 2010, 285, 36849-36856.
58. Brisdelli F.; D'Andrea, G.; Bozzi, A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr. Drug Metab., 2009, 10, 530-546.
59. Hubálek, F.; Binda, C.; Khalil, A.; Li, M.; Mattevi, A.; Castagnoli, N.; Edmondson, D.E. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J. Biol. Chem., 2005, 280, 15761-15766.
60. Burke, Y.D.; Stark, M.J.; Roach, S.L.; Sen, S.E.; Crowell, P.L. Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. Lipids, 1997, 32, 151-156.
61. Wang, Z.; Chen, H.T.; Roa, W.; Finlay, W. Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. J. Pharm. Pharm. Sci. 2003, 6, 95-100.
62. Voziyan, P.A.; Goldner, C.M.; Melnykovych, G. Farnesol inhibits phosphatidylcholine biosynthesis in cultured cells by decreasing cholinephosphotransferase activity. Biochem. J., 1993, 295, 757-762.
63. Miquel, K.; Pradines, A.; Tercé, F.; Selmi, S.; Favre, G. Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. J. Biol. Chem., 1998, 273, 26179-26186.
64. Anthony, M.L.; Zhao, M.; Brindle, K.M. Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J. Biol. Chem., 1999, 274, 19686-19692.
65. Wright, M.M.; Henneberry, A.L.; Lagace, T.A.; Ridgway, N.D.; McMaster, C.R. Uncoupling farnesol-induced apoptosis from its inhibition of phosphatidylcholine synthesis. J. Biol. Chem., 2001, 276, 25254-25261.
66. Cavalli, A.; Bolognesi, M.L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51, 347-372.
67. Kokel, D.; Bryan, J.; Laggner, C.; White, R.; Cheung, C.Y.; Mateus, R.; Healey, D.; Kim, S.; Werdich, A.A.; Haggarty, S.J.; Macrae, C.A.; Shoichet, B.; Peterson, R.T. Rapid behavior-based identification of neuroactive small molecules in the zebrafish. Nat. Chem. Biol., 2010, 6, 231-237.
68. Schwarzschild, M.A. Rasagiline in Parkinson's disease. N. Engl. J. Med., 2010, 362, 658.
69. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.E.; Mattevi, A. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J. Med. Chem., 2007, 50, 5848-5852.